6 December 2016 - PHARMAC is seeking feedback on a proposal to amend the contractual terms of listing for clostridium botulinum type A toxin (Botox) 100 units vial, following a provisional agreement with Allergan.

• The net price for Botox inj 100 u vial would reduce from 1 April 2017 via a confidential rebate applied to all sales to DHB hospitals.
  

• Botox and Dysport have different potencies, meaning doses are different and prices are not directly comparable unit for unit.
• At a dose equivalency of 3:1 Botox would be the most cost effective treatment option for DHBs, compared to Dysport

• Botox would have protection from purchase price reduction, delisting and application of indication restrictions until 31 March 2020.
  
• There would be no changes to the listing of the other brand of clostridium botulinum type A toxin (Dysport) currently listed in the Hospital Medicines List for use in DHB hospitals.
  

Read PHARMAC consultation